A National Genomic Framework for Breast Cancer Risk Stratification in UAE

Breast cancer is a disease that strikes women across the globe, yet the reasons why some develop it while others do not are often hidden in the complex code of human DNA. For decades, scientists have known that risk comes from two main sources: rare, powerful mutations in specific genes that act like a heavy switch, and the combined effect of thousands of tiny, common genetic variations that act like a gentle slope, slowly tilting the balance. While medical teams have learned to spot the heavy switches in people of European descent, they have struggled to understand how these genetic risks play out in other parts of the world, particularly in the Middle East. This gap in knowledge has left many populations without clear guidance on who is most vulnerable or when they should begin screening. The United Arab Emirates has taken a bold step to fill this void by launching a national effort to sequence the genomes of its entire citizenry, creating a massive library of genetic data linked to real-world health records. This initiative offers a rare chance to look at the full picture of inherited cancer risk within a single, diverse population, moving beyond guesswork to see exactly how genetic factors shape the lives of women in the region.

In a landmark study published in October 2026, researchers harnessed this unprecedented resource to map the genetic landscape of breast cancer risk for women in the UAE. By analyzing the DNA of nearly 230,000 Emirati women and cross-referencing it with over a decade of medical history, the team built a comprehensive framework to identify who is at risk and why. They looked for two distinct types of genetic signals: the rare, high-impact mutations in genes known to cause cancer, and the cumulative weight of common genetic variations that are harder to spot individually but powerful when added together. The results revealed a genetic profile unique to this population, showing that certain dangerous gene variants are far more common here than in global databases, while also proving that a risk model developed for Europeans could surprisingly predict risk in Emirati women, albeit with some adjustments.

The study began by scanning the DNA of the participants for errors in thirteen specific genes that are widely recognized as drivers of breast cancer. The researchers found that about 0.84% of the women in the study carried a harmful mutation in one of these genes. While this might seem like a small number, it accounted for more than five percent of all the breast cancer cases diagnosed in the group. What made these findings particularly striking was the discovery of specific mutations in the BRCA1 and BRCA2 genes that were up to ten times more frequent in the Emirati population than in global reference groups. These specific genetic errors were not just common; they were highly dangerous. The data showed that women carrying these specific mutations faced a 37.6% chance of developing breast cancer by the age of 60, a risk that climbed even higher as they aged. This confirmed that for a significant portion of the population, the risk is driven by these powerful, inherited switches that turn on much earlier than in Western populations, where the median age of diagnosis is often a decade later.

However, the researchers quickly realized that looking only at these rare, high-impact mutations told only part of the story. Since these mutations explained only a small fraction of all the cancer cases, the team turned their attention to polygenic risk scores, a method that adds up the effects of thousands of tiny genetic variations to create a single risk number. They tested models originally designed for people of European, East Asian, and African ancestry. Surprisingly, the model built from European data performed the best, accurately distinguishing between women who developed cancer and those who did not. This suggested that the genetic makeup of the Emirati population shares enough similarities with European groups for these tools to work, a finding that was further supported by the observation that Emirati individuals cluster genetically closer to European populations than to other groups.

The power of this polygenic approach became clear when the researchers looked at the timing of the disease. They found that women with the highest genetic risk scores faced a ten-year risk of developing breast cancer that was roughly equivalent to the average woman's risk, but they reached that level of danger ten years earlier in life. A woman in the top tenth of risk could face a significant threat by age 50, whereas a woman with a lower score might not reach that same level of risk until age 60. This shift in timing is crucial for public health, as it suggests that screening programs could be tailored to start earlier for those with high genetic loads, potentially catching the disease before it becomes life-threatening.

The study also delved into the role of family history, reconstructing over 48,000 family trees to see how risk travels through generations. They found that while some families had multiple members with cancer, the vast majority of cases occurred in women with no other affected relatives. This indicated that the young age of diagnosis seen in Emirati women is a broad population characteristic rather than the result of a few large, high-risk families dominating the statistics. Even within families where no one carried a rare, high-impact mutation, the researchers observed that women who developed cancer tended to have higher polygenic risk scores than their unaffected sisters. This confirmed that the "gentle slope" of common genetic variations plays a significant role in clustering risk within families, even when the "heavy switches" are absent.

Ultimately, this work establishes a new national framework for understanding breast cancer in the Middle East. It moves beyond the old assumption that genetic risk models from the West apply universally without change, and it moves beyond the idea that only rare mutations matter. By combining the search for rare, powerful gene errors with the measurement of common, cumulative genetic risks, the researchers have created a tool that can stratify the population into different risk groups. This allows for a more precise approach to prevention, where resources can be focused on those who need them most, regardless of whether their risk comes from a single broken gene or the accumulation of many small ones. The study does not claim to have solved the problem of breast cancer, but it has provided the first clear, data-driven map of the genetic terrain for an entire nation, offering a foundation for early detection and personalized care that was previously impossible.